Login to Your Account

The Power of T Cells

Immunocore, Genentech Seal Multitarget, High-Dollar Deal

By Nuala Moran
Staff Writer

Wednesday, July 3, 2013
LONDON – Fourteen years of pursuing the objective of breaking T-cell tolerance to cancer cells has finally paid off for Immunocore Ltd. in a multitarget deal with Genentech Inc. (now part of Roche AG) worth a potential $320 million or more per program, plus royalties.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription